1) Bantick RA, Deakin JFW, Grasby PM:The 5-HT1A receptor in schizophrenia:A promising target for novel atypical neuroleptics? J Psychopharmacol 15:37-46, 2001
2) Barrett JE, Witkin JM:Buspirone in animal models of anxiety, in Buspirone:Mechanisms and Clinical Aspects. In:Tunnicliff G, Eison AS, Taylor DP, ed. Academic, San Diego, CA. pp37-79, 1991
3) Brenner HD, Dencker SJ, Goldstein MJ, et al:Defining Treatment refractoriness in schizophrenia. Schizophrenia Bull 16:551-561, 1990
4) Cantillon M:A double-blind trial for agitation in a nursing home population with Alzheimer's disease. Am J Geriatr Psychiatry 4:263-267, 1996
5) Goff DC, Midha KK, Brotman AW, et al:An open trial of buspirone added to neuroleptics in schizophrenic patients. J Clin Psychopharmacol 11:193-197, 1991
6) Herrmann N:Buspirone in the management of agitation and aggression associated with dementia. Am J Geriatr Psychiatry 1:249-253, 1993
7) Mintzer JE:Underlying mechanisms of psychosis and aggression in patients with Alzheimer's disease. J Clin Psychiatry 62(Suppl 21):23-25, 2001
8) Schmidt AW, Lebel LA, Howard HR Jr, et al:Ziprasidone:A novel antipsychotic agent with a unique human receptor binding profile. Eur J Pharmacol 425:197-201, 2001
9) 清水宏志,嘉来宣之,広瀬彰,他:SM-3997とラット脳内セロトニン受容体との相互作用.Japan J Pharmacol 46:311-314, 1988
10) 清水宏志,加藤照文,荒木美乃,他:Tandospironeの中枢神経系に対する作用.基礎と臨床 26:1681-1695,1992
11) Sumiyoshi T, Matsui M, Nohara S, et al:Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment. Am J Psychiatry 158:1722-1725, 2001
12) Sumiyoshi T, Matsui M, Yamashita I, et al:The effect of tandospirone, a serotonin(1A)agonist, on memory function in schizophrenia. Biol Psychiatry 49:861-868, 2001
13) 山根秀夫,増井晃,山田尚登,他:痴呆患者の攻撃性に対するtandospironeの有用性と改良長谷川式簡易知能評価スケールおよびBehave-ADとの関連性の検討.臨精薬理 5(増刊号):11-17,2002
14) Yoshimura H, Ogawa N:Ethopharmacology of maternal aggression in mice:effects of diazepam and SM-3397. Eur J Pharmacology 200:147-153, 1991